

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Health Technology Evaluation**

**Equality impact assessment – Scoping**

**Mirikizumab for treating moderately to severely active ulcerative colitis  
(ID3973)**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes – Stakeholders have highlighted certain socioeconomic challenges relating to the cost of prescription medications and that this may be a barrier to well-being and adherence

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Prescription charges are outside of the committee's remit, however the committee will consider the range of treatments and where they are prescribed in determining the most suitable comparators within the appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No

**Approved by Associate Director (name):** Henry Edwards

**Date:** 24/08/2022